EN DE
Watch Cryosite Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cryosite Ltd (CTE) fair value: what the stock is really worth

As of Oct 26, 2026: fair value (intrinsic value) of Cryosite Ltd stock A$0.80, price A$1.22, that is 34.4% below the price, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000CTE1

CL Cryosite Ltd logo Thin data Nov 7, 2026

Cryosite Ltd

CTE · AU
Expensive, weak quality

Our calculation puts a fair price 34% below what the stock costs today.

Solidly profitable · 13.4% net margin (TTM)
62% return on equity.
Quality 43/100
Expensive Growth (revenue 5y +10.7 %/yr in AUD)
Moderate debt
Mixed vs. peers (8/14)
Wide moat 71/100 · thin data
Fair value A$0.8000 · Overvalued
Negative free cash flow
Thin data
⚠ Thinly traded⚠ Small free float
Watch Cryosite Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$1.30 A$0.2853 Fair Value A$0.8000 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range A$0.2853 – A$1.30 · fair‑value band A$0.5600 – A$1.04 · the A$1.22 price screens above the A$0.8000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.

Follow Cryosite in your weekly email

Every Wednesday you see whether Cryosite is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments.

Show moreShow less

The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements.

The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage.

The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls.

It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.

Stock analysis

Cryosite Ltd (CTE) currently trades at A$1.22, while our model-based Fair Value estimate is A$0.8000, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of A$0.8850 per share, and 1 of the 16 models we run sit above the A$1.22 price.

Bear case: the Dividend Discount group reads lowest at A$0.3950, and 15 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: A$0.5600 (bear) to A$1.04 (bull), the price of A$1.22 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cryosite Ltd reported revenue of A$16.7M in FY2026 versus A$11.8M in FY2022, a compound +9.2%/yr. Reported net income was A$2.2M in FY2026, compounding +13.1%/yr from FY2022.

Key figures

Market cap A$63.7M (≈ $43.9M) Micro · P/E ratio 30.5 · P/S ratio 3.81 · EPS (TTM) A$0.0400 · Dividend yield 1.6% · Net margin 13.4% · Return on equity 61.8% · Return on assets (EBIT) 10.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −34%, CTE screens richer than that median.

Fair Value models

Bear A$0.5600 Fair Value A$0.8000 Bull A$1.04
Price A$1.22 · Downside -34.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (A$0.0145 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV A$0.4000 A$0.4800 A$0.5600 74
Residual Income A$0.2800 A$0.3800 A$0.8000 71
ROIC Compounder A$0.4500 A$0.6200 A$0.8300 71
All 16 models by family
Earnings-Based
Graham-Dodd A$0.3100 A$1.24 A$1.69 64
Lynch FV A$0.3100 A$0.4400 A$0.5700 61
PEG = 1.0 A$0.3100 A$0.4400 A$0.5700 57
EPV A$0.4000 A$0.4800 A$0.5600 74
Dividend Discount
Gordon GGM A$0.2000 A$0.4400 A$0.7500 65
DDM Multi-Stage A$0.2000 A$0.3500 A$0.4500 66
Multiples
P/E Multiple A$0.7600 A$1.01 A$1.26 63
P/S Multiple A$0.5800 A$0.7800 A$0.9700 58
P/B Multiple A$0.3300 A$0.4500 A$0.5600 55
EV/EBIT A$0.7100 A$0.9900 A$1.26 66
EV/EBITDA A$0.7600 A$1.06 A$1.35 67
EV/Revenue A$0.4800 A$0.7300 A$0.9800 53
Asset-Based
NCAV (Graham) A$0.0500 A$0.0700 A$0.1000 54
Economic Profit
Residual Income A$0.2800 A$0.3800 A$0.8000 71
ROIC Compounder A$0.4500 A$0.6200 A$0.8300 71
Growth Earnings
Growth-Adj P/E A$0.5600 A$0.8000 A$1.04 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 65
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 26
Does it invest with discipline instead of growing at any price?
Low Volatility 79
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 54
Distance to the 52-week high, does not count
New shares 36
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2021 (pandemic). Over 10 years: +5.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.9%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 8.9% / 18.2%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 19%
Pace: the 5-year rate starts in 2021 (pandemic)

CTE screens overvalued: fair value 34% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Cryosite Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −34.4% · Below median
Profitability
Return on equity (12 months) 61.8% · Top 25%
Return on assets 8.6% · Top 25%
Net margin (12 months) 13.4% · Above median
Operating margin (12 months) 18.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 12.7% · Above median
Dividend yield (12 months) 1.6% · Above median
Balance sheet
Debt / equity 1.17× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 30.5× · Cheaper than median
P/B 13.13× · Priciest 25%
P/S (12 months) 3.81× · Pricier than median
EV/EBITDA 18.9× · Pricier than median
PEG 1.53× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)64 · sector 39
PAST (return on equity)100 · sector 15
HEALTH (low debt)42 · sector 95
DIVIDEND (yield)33 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs CTE
IQVIA Holdings IQV $271.83 $299.01 +10% vs CTE
Illumina, Inc ILMN $213.13 $234.44 +10% vs CTE
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs CTE
Danaher Corporation DHR $230.25 $209.18 −9% vs CTE
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs CTE
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs CTE
Agilent Technologies, Inc A $174.76 $64.53 −63% vs CTE
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs CTE
Waters Corporation WAT $457.60 $91.26 −80% vs CTE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cryosite Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cryosite Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CTE

Frequently asked questions

Is Cryosite Ltd (CTE) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of A$0.8000 versus the last price from Oct 26, 2026 of A$1.22, about 34% lower (overvalued).
What is the fair value of CTE?
Our model-based fair value for Cryosite Ltd is A$0.8000 (as of Nov 7, 2026), built from audited fundamentals. Last price (from Oct 26, 2026): A$1.22.
What is the quality score of CTE?
Cryosite Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cryosite Ltd (CTE)?
Our model-based price target is the fair value of A$0.8000 (as of Nov 7, 2026) from 16 valuation models. Cautious scenario A$0.5600, optimistic scenario A$1.04. It is a calculation from audited fundamentals, not an analyst target.
What is the Cryosite Ltd stock forecast for 2026?
Our models put fair value at A$0.8000, about 34% lower versus the last price from Oct 26, 2026 of A$1.22 (overvalued). Cautious scenario A$0.5600, optimistic scenario A$1.04. The calculation is refreshed regularly with new filings.
What is the revenue of Cryosite Ltd (CTE)?
Cryosite Ltd reported trailing-twelve-month revenue of about A$16.7M (latest available figure, as of Nov 7, 2026).
Does Cryosite Ltd pay a dividend?
Cryosite Ltd currently shows a dividend yield of 1.64% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Cryosite Ltd (CTE)?
Cryosite Ltd has a dividend yield of 1.6%.
What is the intrinsic value of Cryosite Ltd (CTE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cryosite Ltd it is A$0.8000 per share (as of Nov 7, 2026), against a price of A$1.22. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Cryosite Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, CTE trades above its calculated fair value: price A$1.22, fair value A$0.8000, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTE?
No. The price is what the market pays today (A$1.22); the fair value is what the company's own numbers justify (A$0.8000). For Cryosite Ltd the two are A$0.4200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cryosite Ltd worth?
The market values Cryosite Ltd at about A$63.7M (market capitalisation, as of Nov 7, 2026). Per share that is A$1.22; our models calculate a fair value of A$0.8000 per share.
What do the bullish and bearish scenarios say about CTE?
Our models span a range for Cryosite Ltd: cautious scenario A$0.5600, base A$0.8000, optimistic A$1.04 per share (as of Nov 7, 2026, price A$1.22). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CTE?
Cryosite Ltd trades at a price-to-earnings ratio of 30.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.8000 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2020 to 2026), reported earnings: 22.6. Other multiples: PEG 1.5, P/B 13.1, P/S 3.8, EV/EBITDA 18.9.
What is the PEG ratio of CTE?
The PEG ratio of Cryosite Ltd is 1.53 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Cryosite Ltd (CTE)?
Balance-sheet figures for Cryosite Ltd (as of Nov 7, 2026): return on equity 61.8%, debt of 1.17 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is CTE from its 52-week high?
Cryosite Ltd trades at A$1.22, about 6% below its 52-week high of A$1.30 and 22% above the low of A$1.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.8000 is for.
Which stocks are comparable to Cryosite Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cryosite Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price A$1.22, calculated fair value A$0.8000 (−34%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTE calculated?
We run Cryosite Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$0.8000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cryosite Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cryosite Ltd (CTE)?
The latest price we hold is from Oct 26, 2026 and stands at A$1.22. Our model-based fair value is A$0.8000, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cryosite Ltd right now?
The price sits above even our optimistic bull case (A$1.04). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.5600 to A$1.04) leaves room in how you read the outcome.
Where does the earnings growth of Cryosite Ltd (CTE) come from?
Earnings per share at Cryosite Ltd grew +18.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +3.5 %, EBIT margin +17.6 %, tax rate +0.6 %, residual (interest, one-offs) −3.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Cryosite Ltd

How large is the market capitalisation of Cryosite Ltd (CTE)?
The market capitalisation of Cryosite Ltd is A$63.7M (≈ $43.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cryosite Ltd (CTE)?
The price-to-sales ratio of Cryosite Ltd is 3.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cryosite Ltd (CTE)?
Earnings per share at Cryosite Ltd are A$0.0400 (price ÷ EPS = P/E 30.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cryosite Ltd (CTE)?
The dividend yield of Cryosite Ltd is 1.6% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cryosite Ltd (CTE)?
The net margin of Cryosite Ltd is 13.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cryosite Ltd (CTE)?
The return on equity (ROE) of Cryosite Ltd is 61.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cryosite Ltd (CTE)?
On an EBIT basis the return on assets of Cryosite Ltd is 10.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cryosite Ltd (CTE)?
The operating margin of Cryosite Ltd is 18.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cryosite Ltd (CTE)?
Revenue at Cryosite Ltd is growing +12.7% versus a year earlier (3y avg +11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cryosite Ltd (CTE)?
Earnings per share at Cryosite Ltd are growing +2.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cryosite Ltd (CTE) generate?
The free cash flow of Cryosite Ltd is −A$8.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cryosite Ltd (CTE) carry?
The net debt of Cryosite Ltd is A$5.5M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cryosite Ltd in the live analysis

One click puts Cryosite Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.